BIOPHTA

BIOPHTA is a French biotechnology company based in Paris, founded in 2020.

It focuses on developing innovative solutions for ophthalmology, aiming to create a non-invasive alternative to daily eye drops and invasive injections for eye diseases. The company is co-founded by experienced pharmacists Jean Cuiné and Jean Garrec, who bring over 40 years of expertise in ophthalmology and drug development. BIOPHTA's core technology is based on a proprietary platform of biopolymers known as thiomers. Their primary product is a self-administered, bio-adhesive ophthalmic insert that transforms into a hydrogel upon application to the eye. This insert provides a controlled release of medication over seven days, offering a patient-friendly option for treating various ophthalmic conditions, including glaucoma and diabetic macular edema. The company is currently advancing its technology toward clinical trials, having secured €6.5 million in Seed funding to support this transition.